Business
Spectral AI Strengthens Financial Position Ahead of FDA Submission
DALLAS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the satisfaction of its final remaining obligations under the Company’s debt facility with Yorkville Advisors. The Company retains access to addi
About this update from Spectral Ai, Inc.
[{"type":"image","alt":"Spectral AI, Inc.","displaySize":"","headline":null,"caption":"Spectral AI, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/23a9fc91c43a2f0647ed42a9076103ab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NMHcc5qGUB2OTcJyeAvzUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/23a9fc91c43a2f0647ed42a9076103ab","width":150,"height":78}},"lazy":false},{"type":"text","content":"DALLAS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced the satisfaction of its final remaining obligations under the Company’s debt facility with Yorkville Advisors. The Company retains access to additional financing of up to $17.5 million under an existing standby equity purchase agreement.","length":592,"tagName":"p"},{"type":"text","content":"“I am pleased to share this milestone as we continue advancing toward our FDA submission and work to bring our technology to burn care institutions across the U.S.,” said Dr. J. Michael DiMaio, MD, Chairman of the Board at Spectral AI.","length":235,"tagName":"p"},{"type":"text","content":"About Spectral AI ","length":17,"tagName":"p"},{"type":"text","content":"Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. The DeepView® System is a predictive device that offers clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView® System is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information a...